Soluble CTLA4 mutant molecules and uses thereof

Details for Australian Patent Application No. 2004201287 (hide)

Owner Bristol-Myers Squibb Company

Inventors Bajorath, Jurgen; Linsley, Peter S; Naemura, Joseph Roy; Peach, Robert James

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004201287

Parent 10030

Filing date 26 March 2004

Wipo publication date 29 April 2004

International Classifications

C07K 014/725 Peptides having more than 20 amino acids

A61K 039/00 Medicinal preparations containing antigens or antibodies

C12N 015/12 Mutation or genetic engineering - Genes encoding animal proteins

A61P 037/06 Drugs for immunological or allergic disorders

Event Publications

22 April 2004 Complete Application Filed

29 April 2004 Application Open to Public Inspection

  Published as AU-A-2004201287

21 August 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004201288-Robot cleaner having air cleaning function and system thereof

2004201286-Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B